Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has become a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogenesis
Autors principals: Yeh, Chi-Tai, Chen, Tzu-Tao, Satriyo, Pamungkas Bagus, Wang, Chun-Hua, Wu, Alexander T. H., Chao, Tsu-Yi, Lee, Kang-Yun, Hsiao, Michael, Wang, Liang-Shun, Kuo, Kuang-Tai
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316404/
https://ncbi.nlm.nih.gov/pubmed/34315851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-021-00345-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars